Cusatuzumab
- Generic Name
- Cusatuzumab
- Brand Names
- -
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 1864871-20-4
- Unique Ingredient Identifier
- RR5U4UFJ8L
- Background
CD70 is a ligand expressed on the surface of activated lymphocytes and mature dendritic cells that, in its binding to CD27 receptors, plays an important role in cell proliferation and survival. An overexpression of CD70 can result in the proliferation of malignant cells and has been documented in a variety of solid and hematological malignancies.
...
- Associated Conditions
- -
- Associated Therapies
- -
A Study Comparing Venetoclax and Azacitidine Plus Cusatuzumab to Venetoclax and Azacitidine in Newly Diagnosed AML Ineligible for Intensive Therapy
- Conditions
- Interventions
- First Posted Date
- 2024-04-25
- Last Posted Date
- 2024-11-26
- Lead Sponsor
- OncoVerity, Inc.
- Target Recruit Count
- 120
- Registration Number
- NCT06384261
- Locations
- 🇺🇸
The University of Iowa Hospitals & Clinics, Iowa City, Iowa, United States
🇨🇦Tom Baker Cancer Center-Alberta Health Services - University of Calgary, Calgary, Alberta, Canada
🇨🇦Stollery Children's Hospital-Walter C Mackenzie Health Sciences Centre - University of Alberta, Edmonton, Alberta, Canada
A Study of Cusatuzumab in Combination With Azacitidine Compared With Azacitidine Alone in Patients With Higher-risk Myelodysplastic Syndrome (MDS) or Chronic Myelomonocytic Leukemia (CMML) and Who Are Not Candidates for Hematopoietic Stem Cell Transplantation (HSCT)
- Conditions
- Interventions
- First Posted Date
- 2020-02-11
- Last Posted Date
- 2022-05-20
- Lead Sponsor
- Janssen Research & Development, LLC
- Registration Number
- NCT04264806
- Locations
- 🇸🇦
King Faisal Specialist Hospital & Research Center, Riyadh, Saudi Arabia
🇨ðŸ‡UniversitaetsSpital Zuerich, Zürich, Switzerland
🇦🇺St Vincents Hospital Sydney, Darlinghurst, Australia
A Study of Cusatuzumab Plus Azacitidine in Japanese Participants With Newly Diagnosed Acute Myeloid Leukemia or High-risk Myelodysplastic Syndrome Who Are Not Candidates for Intensive Treatment
- First Posted Date
- 2020-01-27
- Last Posted Date
- 2023-08-09
- Lead Sponsor
- OncoVerity, Inc.
- Target Recruit Count
- 6
- Registration Number
- NCT04241549
- Locations
- 🇯🇵
Fukushima Medical University Hospital, Fukushima, Japan
🇯🇵Osaka City General Hospital, Osaka, Japan
🇯🇵University of Fukui Hospital, Yoshida, Japan
Cusatuzumab in Combination With Background Therapy for the Treatment of Participants With Acute Myeloid Leukemia
- Conditions
- Interventions
- First Posted Date
- 2019-11-05
- Last Posted Date
- 2024-07-22
- Lead Sponsor
- OncoVerity, Inc.
- Target Recruit Count
- 61
- Registration Number
- NCT04150887
- Locations
- 🇵🇱
Szpital Uniwersytecki w Krakowie, Krakow, Poland
🇨ðŸ‡Kantonsspital St.Gallen, St. Gallen, Switzerland
🇵🇱Wojewodzkie Wielospecjalistyczne Centrum Onkologii i Traumatologii im. M. Kopernika w Lodzi, Lodz, Poland
A Study of Cusatuzumab Plus Azacitidine in Participants With Newly Diagnosed Acute Myeloid Leukemia Who Are Not Candidates for Intensive Chemotherapy
- Conditions
- Interventions
- First Posted Date
- 2019-07-17
- Last Posted Date
- 2024-07-30
- Lead Sponsor
- OncoVerity, Inc.
- Target Recruit Count
- 103
- Registration Number
- NCT04023526
- Locations
- 🇮🇱
Hadassah Medical Center, Jerusalem, Israel
🇷🇺Oncologic Dispensary No.2, Sochi, Russian Federation
🇷🇺Komi Republic Oncology dispensary, Syktyvkar, Russian Federation
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.